PDS Biotechnology Corporation (PDSB): Business Model Canvas [Apr-2026 Updated]

You're looking at a late-stage immunotherapy firm, trying to see past that zero-dollar product revenue line-that's defintely where the real story is for PDS Biotechnology Corporation (PDSB) right now. Their entire business model is currently staked on executing the pivotal Phase 3 VERSATILE-003 trial for PDS0101, supported by strategic partners like Merck and the NCI. With cash sitting at $26.2 million as of September 30, 2025, and burning roughly $4.6 million on R&D in Q3 2025, the runway is tied directly to clinical progress and regulatory wins. This isn't about sales yet; it's about milestones. The value proposition rests squarely on showing that extended survival-like the 39.3 months median overall survival seen before-can translate into an accelerated FDA pathway. Check out the full breakdown below to see how PDS Biotechnology Corporation (PDSB) is managing its key resources and costs to reach that inflection point.

PDS Biotechnology Corporation (PDSB) - Canvas Business Model: Key Partnerships

You're looking at the core relationships that fuel PDS Biotechnology Corporation's late-stage pipeline, especially as they push the VERSATILE-003 trial forward. These aren't just handshake agreements; they involve significant clinical and regulatory alignment.

The collaboration with Merck, centered around the use of Keytruda® (pembrolizumab), is central to the registrational path for Versamune® HPV. This partnership underpins the ongoing Phase 3 VERSATILE-003 trial, which is designed to evaluate the combination therapy against pembrolizumab alone. The design calls for enrolling approximately 350 patients, randomized in a 2:1 ratio favoring the investigational arm.

The data informing this Phase 3 strategy comes directly from the completed VERSATILE-002 study, which used the same combination in recurrent/metastatic HPV16-positive head and neck cancer. Here's a snapshot of those key Phase 2 results, which PDS Biotechnology Corporation is using to seek an expedited approval pathway:

This data definitely suggests a meaningful step up in efficacy when using the combination therapy. Anyway, the company's cash position as of September 30, 2025, stood at $26.2 million, which means funding these global trial sites is a constant focus.

PDS Biotechnology Corporation also maintains critical academic and governmental research alliances that help expand the platform beyond HPV. These relationships provide access to specialized trial infrastructure and novel combination strategies.

• Strategic research collaboration with the National Cancer Institute (NCI) under a Collaborative Research and Development Agreement (CRADA).
• The NCI is supporting a Phase 2 clinical study of PDS0301 in checkpoint inhibitor refractory patients.
• The colorectal cancer cohort of the PDS01ADC trial, part of the NCI agreement, progressed to Stage 2 enrollment as of August 2025.
• Mayo Clinic is directly involved, with one of its oncologists serving as the Principal Investigator for the global Phase 3 VERSATILE-003 trial.
• Mayo Clinic also presented results from its MC 200710 study featuring Versamune HPV in May 2025.

The VERSATILE-003 trial itself is a massive logistical undertaking, relying on a global network of clinical sites. PDS Biotechnology Corporation announced the initiation of the first trial site in March 2025, with activation of additional sites continuing throughout 2025 to meet the target enrollment of approximately 350 patients.

Also, remember the deal with Merck KGaA, Darmstadt, Germany, for PDS0301 (the IL-12 fusion protein). That deal included an upfront cash payment of $5 million to Merck KGaA, Darmstadt, Germany, plus potential milestone payments up to $11 million and a 10% royalty on future sales.

Finance: review cash burn against Q3 2025 operating expenses of $8.1 million by next Tuesday.

PDS Biotechnology Corporation (PDSB) - Canvas Business Model: Key Activities

You're managing the core operational focus for PDS Biotechnology Corporation as we move through late 2025. The key activities center squarely on advancing the lead asset through pivotal trials and securing the regulatory pathway.

Executing the pivotal Phase 3 VERSATILE-003 clinical trial.

The primary operational activity is the execution of the VERSATILE-003 Phase 3 randomized, controlled, global, multi-center trial. This trial is evaluating the safety and efficacy of PDS0101 (Versamune® HPV) in combination with pembrolizumab as a first-line treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC). The trial was initiated in the first quarter of 2025.

The structure of the trial involves enrolling approximately 350 patients, randomized in a 2:1 ratio between the investigational arm (PDS0101 + pembrolizumab) and the control arm (pembrolizumab alone). The original primary endpoint for full approval is Median Overall Survival (mOS).

Research and development (R&D) of the Versamune® and PDS01ADC platforms.

PDS Biotechnology Corporation continues its R&D to support and expand its proprietary platforms, Versamune® and PDS01ADC, an IL-12 fused antibody drug conjugate. This work underpins the development of PDS0101 and other pipeline candidates, including PDS01ADC in NCI-led Phase 1/2 trials for colorectal cancer.

Here are some recent financial markers for this activity:

• Research and development expenses for the three months ended September 30, 2025, totaled $4.6 million.
• Research and development expenses for the three months ended March 31, 2025, were $5.8 million.

The company remains focused on translating the immunological properties demonstrated in preclinical and early clinical studies into tangible patient benefits.

Seeking regulatory approval, including the FDA Type C meeting for accelerated approval.

A critical, near-term activity is engaging the U.S. Food and Drug Administration (FDA) to potentially shorten the path to market for PDS0101. PDS Biotechnology Corporation secured an FDA Type C Meeting scheduled for December 2025 to discuss a proposed amendment to the VERSATILE-003 trial.

The proposed amendment seeks to use Progression-Free Survival (PFS) as a surrogate primary endpoint for accelerated approval, based on positive data from the completed VERSATILE-002 trial. The company expects to receive the FDA meeting minutes in January 2026. PDS0101 has already received Fast Track designation from the FDA.

You need to keep the results from the VERSATILE-002 trial top of mind:

The company reported a net loss of $9.0 million, or $0.19 per share, for the third quarter of 2025, and the cash balance as of September 30, 2025, was $26.2 million. That cash position is what funds these key activities.

Intellectual property management and patent defense (through mid-2030s).

Protecting the core technology is a non-negotiable activity, as the company's ability to protect its intellectual property rights is explicitly noted as a factor affecting its prospects. The IP portfolio governs the proprietary combination of Versamune®-based therapies and PDS01ADC.

Key IP assets include:

• U.S. Patent No. 11,401,306, covering the combination of Versamune® and Interleukin 12 (IL-12).
• Canadian Patent No. 2,876,656, covering composition of matter and uses for Versamune® in combination with PDS01ADC.

This protection is designed to cover commercialization and partnership strategies well into the 2030s.

PDS Biotechnology Corporation (PDSB) - Canvas Business Model: Key Resources

You're looking at the core assets PDS Biotechnology Corporation (PDSB) is relying on to drive value in late 2025. It's a classic biotech setup: heavy reliance on proprietary science, a lead clinical asset, and the cash runway to fund the next steps. Honestly, the numbers tell a story of high potential balanced by immediate financial pressure.

• Proprietary Versamune® T cell activating platform technology.

The Versamune® platform is a cationic, lipid-based nanoparticle technology. Its design goal is to recruit, train, and arm T cells for a precise attack against the targeted disease. This platform is engineered for simplicity, administered via a simple subcutaneous injection, and has shown a favorable safety profile, with side effects limited predominantly to transient injection site reactions. PDS Biotechnology Corporation holds several patents covering the technology in major markets, including the US, Europe, and Japan, providing technology and product protection through at least the mid-2030s. The platform is also used in PDS01ADC, an IL-12 fused antibody drug conjugate (ADC) designed to specifically target and deliver IL-12 into the tumor microenvironment.

• Lead investigational asset PDS0101 (Versamune® HPV).

PDS0101 is the company's lead candidate, specifically targeting HPV16-positive cancers. The final topline survival data from the Phase II VERSATILE-002 trial was a major resource highlight, showing durable clinical benefit. PDS Biotechnology Corporation is now actively seeking to leverage these results in its ongoing pivotal trial. The company has initiated a request for a Type C Meeting with the FDA, scheduled for December 2025, to discuss amending the VERSATILE-003 Phase 3 trial. This proposed amendment would change the Progression-Free Survival (PFS) endpoint to a surrogate primary endpoint to potentially accelerate the path to regulatory submission, while Median Overall Survival (mOS) remains the primary endpoint for full approval. The VERSATILE-003 registrational trial was initiated in March 2025.

Here's a quick look at the key clinical and financial metrics underpinning the value of PDS0101 and the platform as of late 2025:

• Cash balance of $26.2 million as of September 30, 2025.

The cash position is a critical near-term resource, reflecting the burn rate associated with clinical development. As of September 30, 2025, PDS Biotechnology Corporation held $26.2 million in cash, a decrease from $41.7 million at the start of the year. The company recently executed a financing on November 12, 2025, bringing in gross proceeds of approximately $5.3 million. This capital is being deployed to support the ongoing pivotal VERSATILE-003 Phase 3 trial, which is the primary use of funds for a development-stage company with no revenue generation as of Q3 2025.

• Core team of experienced clinical development and regulatory personnel.

The human capital is centered around seasoned leadership with deep industry tenure. Frank Bedu-Addo, the President and CEO, has been with PDS Biotechnology Corporation since its inception in 2005, with a total yearly compensation reported at $2.26M in a recent period. Lars Boesgaard, the CFO, joined in December 2023, bringing over 25 years of experience in healthcare capital markets. Dr. David Schaaf, VP of Medical Affairs, has over 20 years of industry experience focused on clinical development and regulatory submissions. The management team's average tenure is 2.8 years, suggesting stability in strategic execution. This team is tasked with navigating the complex regulatory pathway for PDS0101.

PDS Biotechnology Corporation (PDSB) - Canvas Business Model: Value Propositions

You're looking at the core value PDS Biotechnology Corporation (PDSB) is putting forward with its lead asset, PDS0101, especially given the current market sentiment where the company was valued at $39.3 million as of December 2, 2025, despite reporting a net loss of $9 million (or $0.19 per share) for the third quarter of 2025.

The primary value is centered on delivering superior survival outcomes in a difficult-to-treat cancer population, HPV16+ recurrent and/or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), without resorting to chemotherapy.

The potential for an accelerated FDA approval pathway for PDS0101 is a major value driver, as PDS Biotechnology Corporation requested an FDA Type C meeting in December 2025 to discuss amending the Phase 3 VERSATILE-003 trial. This proposed amendment would introduce Progression-Free Survival (PFS) as an earlier primary endpoint, potentially shortening the time to regulatory submission, with minutes expected in January 2026. This strategy hinges on the robust data from the Phase 2 trial.

Here's a look at the survival benchmarks PDS Biotechnology Corporation is using to support this regulatory push:

The data shows an extended median overall survival (mOS) of 39.3 months in the overall population (CPS $\ge$ 1) from the single-arm Phase 2 VERSATILE-002 trial. This is a significant leap over the 17.9 months historically seen with pembrolizumab alone or combined with chemotherapy in this setting.

Furthermore, the value proposition extends to a particularly challenging subset of patients, those with low PD-L1 expression (CPS 1-19, n=32):

• mOS achieved was 29.5 months.
• This compares favorably to published mOS of 10.8 months with Keytruda monotherapy.
• It also beats published mOS of 12.3 months with Keytruda plus chemotherapy in this CPS 1-19 cohort.

The combination offers a novel, well-tolerated immunotherapy combination without chemotherapy. A key supporting fact is that no patients in the VERSATILE-002 trial discontinued treatment due to treatment-related adverse effects (TRAEs). The overall rate of grade 3 TRAEs was 16.1%, with only 1 patient experiencing a grade 4 TRAE, and no grade 5 TRAEs reported.

The mechanism driving this efficacy is the synergistic T-cell activation and tumor microenvironment targeting. PDS0101 is designed to stimulate high levels of long-lasting, multifunctional, HPV16-specific CD8-positive T cells, which then enhance the effect of the immune checkpoint inhibitor.

PDS Biotechnology Corporation is also advancing next-generation approaches, including the development of PDS01ADC, which is an IL-12 fused antibody drug conjugate. This asset is currently being evaluated in multiple Phase 2 trials in combination with standard of care, suggesting a pipeline strategy to further enhance tumor targeting. The company is developing PDS0101 in a triple combination that includes PDS01ADC.

You should review the timeline for the FDA meeting minutes, which are expected in January 2026, as that will dictate the near-term path for the accelerated approval strategy. Finance: draft 13-week cash view by Friday.

PDS Biotechnology Corporation (PDSB) - Canvas Business Model: Customer Relationships

You're managing relationships in a high-stakes, capital-intensive sector, so every interaction with regulators, investigators, and investors is critical for PDS Biotechnology Corporation (PDSB). The focus here is on building trust and securing the necessary runway to bring PDS0101 to market.

High-touch, direct engagement with clinical investigators and key opinion leaders (KOLs)

The relationship with the clinical community is foundational, especially as PDS Biotechnology Corporation advances its lead program, PDS0101, in the pivotal VERSATILE-003 Phase 3 trial. Direct engagement ensures trial integrity and builds advocacy among experts who will ultimately use and champion the therapy.

PDS Biotechnology Corporation highlights its collaborations with several major entities, which serve as key relationship anchors:

• World class partnerships include Merck, MD Anderson Cancer Center, National Cancer Institute, and Mayo Clinic.
• The company hosted a Key Opinion Leader Event to discuss Versamune® HPV for the treatment of HPV16+ HNSCC.
• The colorectal cancer cohort in a study led by the National Cancer Institute demonstrated a promising response rate, with $\geq$ 6 of 9 confirmed objective responses by RECIST v1.1, triggering enrollment expansion.
• Clinical trials, like VERSATILE-002, involve direct engagement with investigators testing PDS0101 in combination with standard-of-care agents like Keytruda® (pembrolizumab).

The final topline survival data from the completed VERSATILE-002 Phase 2 trial, which evaluated PDS0101 + Pembrolizumab, provides the core data for these discussions, showing a Median Overall Survival (mOS) of 39.3 months in patients with CPS $\geq 1$.

Regulatory relationship management with the U.S. Food and Drug Administration (FDA)

Managing the relationship with the U.S. Food and Drug Administration (FDA) is centered on aligning on the path for PDS0101, particularly seeking an expedited route. This is a high-stakes dialogue that directly impacts time-to-market.

As of late 2025, PDS Biotechnology Corporation is actively engaging the agency:

• PDS Biotechnology Corporation announced the FDA accepted its request for a Type C Meeting scheduled for December 2025.
• The purpose of this meeting is to discuss a proposed amendment to the ongoing VERSATILE-003 Phase 3 trial to potentially use Progression-Free Survival (PFS) as a surrogate primary endpoint for accelerated approval.
• The company is clear that mOS will remain the primary endpoint for full FDA approval, which is a key point of negotiation.
• The original design of the registrational Phase 3 VERSATILE-003 trial was aligned with the FDA and is designed to include approximately 350 patients.
• PDS Biotechnology Corporation previously received Fast Track designation from the FDA for the combination of Versamune® HPV and pembrolizumab in R/M HNSCC.

This regulatory focus is grounded in the data from the completed VERSATILE-002 trial, which showed a PFS of 6.3 months and an mOS lower limit of the 95% confidence interval at 23.9 months for the CPS $\geq 1$ cohort.

Investor relations and capital market communication for financing needs

For a late-stage clinical company, investor relations is fundamentally about communicating clinical progress alongside financial stewardship, especially given the cash burn required for Phase 3 trials. You need to keep the capital markets engaged to fund operations.

Here's a look at the financial context and recent capital activities as of late 2025:

The company explicitly disclosed substantial doubt about its ability to continue as a going concern for at least 12 months, making the communication around financing crucial. The $20.0 million securities purchase in early 2025, which included debentures with a high effective annual interest rate of approximately 24.1%, highlights the cost of capital needed to bridge to the next inflection point. The recent November 2025 offering of up to $11.1 million was a direct response to the need to bolster the $26.2 million cash position as of September 30, 2025.

The management team, including President and CEO Frank Bedu-Addo, PhD, must clearly articulate how the potential accelerated approval pathway, discussed with the FDA, de-risks the investment thesis despite the current cash position and going-concern warning. Finance: draft 13-week cash view by Friday.

PDS Biotechnology Corporation (PDSB) - Canvas Business Model: Channels

You're looking at how PDS Biotechnology Corporation (PDSB) gets its value proposition-novel immunotherapies-to its customers, which, at this late-stage, means clinical investigators, scientific peers, and eventually, patients.

Global network of clinical trial sites for patient enrollment and drug delivery

The current channel for drug delivery and patient access is entirely through the clinical trial infrastructure. This network is heavily supported by a Collaborative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) Center for Cancer Research (CCR), which acts as a key channel for trial execution and data generation. The lead program, PDS0101, is advancing through the VERSATILE-003 Phase 3 randomized trial for HPV16-positive recurrent/metastatic head and neck cancer. Furthermore, PDS01ADC is being evaluated across multiple Phase 2 trials conducted under the NCI CRADA across indications including metastatic colorectal cancer, cholangiocarcinoma, and prostate cancer.

The scale of data collection points to an established, albeit clinical, network:

This clinical footprint is the primary channel for delivering the investigational products right now. The research and development expenses for the three months ended September 30, 2025, were $4.6 million, which directly funds the operational costs of these site networks.

Direct scientific publications and presentations at major oncology conferences (e.g., SITC 2025)

Scientific dissemination is a critical channel for establishing credibility, attracting potential partners, and informing future prescribers. PDS Biotechnology Corporation actively uses major medical meetings to communicate data directly to the scientific community. As of late 2025, the company highlighted data presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, which took place November 7 to 8, 2025. This was a significant channel event, featuring one rapid oral abstract, which was recognized among the top 150 abstracts of the meeting, alongside two poster presentations. The oral presentation focused on serum proteomic changes that may predict anti-tumor activity in advanced HPV-associated cancers. This direct scientific engagement is key for a company with projected 2025 revenue of $0.

The output from this channel is measured by the quality and quantity of scientific disclosures:

• Presentations at SITC 2025: 3 total (1 oral, 2 posters).
• Abstract recognition: Top 150 at SITC 2025.
• Prior data presented at AACR 2025 (April 25-30) on PDS01ADC.

This focus on data generation and presentation supports the regulatory strategy to advance toward commercialization.

Future specialized pharmaceutical distribution channels post-commercialization

As PDS Biotechnology Corporation is currently a clinical-stage company with no expected revenue for the full year 2025, specific, detailed plans for specialized pharmaceutical distribution channels post-commercialization are not yet publically quantified in financial filings. The current strategy is focused on advancing PDS0101 toward an expedited approval pathway following positive Phase 2 data from VERSATILE-002. The expectation is that upon potential approval, distribution will require specialized channels appropriate for advanced oncology therapeutics, likely involving limited, high-touch distribution networks, specialty pharmacies, and direct-to-hospital/clinic delivery models, similar to other targeted immunotherapies. The company's cash balance as of September 30, 2025, was $26.2 million, which will need to be supplemented to fund the build-out of these future commercial channels.

PDS Biotechnology Corporation (PDSB) - Canvas Business Model: Customer Segments

You're looking at the specific patient populations PDS Biotechnology Corporation (PDSB) is targeting with its lead asset, Versamune® HPV (PDS0101), and pipeline candidates. This is where the commercial opportunity is defined.

The primary segment is Patients with HPV16-positive recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). This specific, high-need group forms the basis of the company's lead indication and its ongoing Phase 3 VERSATILE-003 trial.

The market potential for this segment alone is estimated to be between $\text{2 to 3 billion}$ in the United States, with a combined opportunity in the United States and Europe estimated at $\text{4 to 5 billion}$ as of early 2025. The underlying patient pool is significant, as it's estimated that over 50% of HNSCC cases in the US are HPV16-positive, with some reports suggesting 60 to 70% of oral cancers are HPV16-positive. This patient group is considered to have a more severe disease and a pressing medical need for targeted therapy.

The data from the completed Phase 2 VERSATILE-002 trial, which enrolled 53 patients in the 1L R/M HNSCC arm, directly informs the value proposition for this segment:

The next segment comprises Oncology specialists and treating physicians in academic and community settings. These are the prescribers and decision-makers who manage the care for the HNSCC patient population. They are motivated by data showing superior survival outcomes compared to the current standard of care, especially in difficult-to-treat subsets.

Physicians treating the low PD-L1 expression subset (CPS 1-19) are presented with a significant treatment gap, as the historical mOS with standard of care in this group was only 10.8 months (Keytruda monotherapy) or 12.3 months (Keytruda + chemotherapy). PDS Biotechnology Corporation is targeting these specialists with data showing a median overall survival of 29.5 months in this specific cohort using PDS0101 plus Keytruda. The company's cash position as of September 30, 2025, was $26.2 million, which reflects the operational scale supporting the ongoing clinical engagement with these specialists.

The final segment involves Patients with other solid tumors in the pipeline (e.g., colorectal, prostate cancer). While the primary focus is HNSCC, PDS Biotechnology Corporation is expanding its reach through other indications utilizing its technology platform.

Specific pipeline activities relevant to this segment include:

• Initiation of a Phase 2 Clinical Trial cohort for Colorectal Cancer using PDS01ADC.
• This Colorectal Cancer cohort met the criteria for Expansion to Stage 2 following positive Stage 1 results.
• Readouts from two ongoing studies at the National Cancer Institute are expected in the first half of 2026.

The company reported a net loss of $9 million for the third quarter ended September 30, 2025, indicating continued investment in advancing these pipeline opportunities alongside the lead program.

Finance: draft 13-week cash view by Friday.

PDS Biotechnology Corporation (PDSB) - Canvas Business Model: Cost Structure

The Cost Structure for PDS Biotechnology Corporation as of the third quarter of 2025 is heavily weighted toward research and clinical development activities, which is typical for a late-stage immunotherapy company reporting no product revenue.

For the three months ended September 30, 2025, the key operating expenses were:

You see that R&D expenses were $4.6 million for the three months ended September 30, 2025, which represented a decrease from $6.8 million in the prior year period. G&A expenses for the same quarter were $3.6 million, an increase from $3.4 million in the prior year period.

The primary drivers and components of these costs include:

• High Research and Development (R&D) expenses, totaling $4.6 million in Q3 2025.
• Clinical trial execution and manufacturing costs for investigational products, which contributed to the R&D spend.
• General and administrative (G&A) expenses, which were $3.6 million in Q3 2025.
• Costs associated with maintaining and defending intellectual property.

The decrease in R&D expenses was primarily due to lower manufacturing and clinical expenses and personnel costs. The increase in G&A expenses was primarily due to higher professional fees, partially offset by lower personnel costs.

PDS Biotechnology Corporation (PDSB) - Canvas Business Model: Revenue Streams

You're looking at a classic late-stage biotech revenue profile right now, which means the current top line is all about financing the pipeline, not product sales. For the three months ended September 30, 2025, PDS Biotechnology Corporation reported $0.0 million in product revenue. That's typical; the focus is entirely on clinical milestones and future commercialization.

The most immediate, tangible cash inflow comes from capital raising activities. PDS Biotechnology Corporation executed a registered direct offering in November 2025. The initial gross proceeds from this transaction were approximately $5.3 million, before accounting for placement agent fees and expenses. This cash is earmarked for continuing the VERSATILE-003 Phase 3 clinical trial for PDS0101 and other R&D needs.

Here's a quick look at the recent financing and cash position as of the end of Q3 2025:

Future revenue streams are entirely contingent on clinical success and subsequent commercialization or partnership agreements. These are the assets driving the long-term value proposition:

• Future product sales of PDS0101 post-regulatory approval.
• Potential milestone payments from the ongoing VERSATILE-003 Phase 3 trial.
• Royalties from PDS01ADC development, which is in NCI-led Phase 2 trials.
• Potential revenue from PDS0101 in combination with PDS01ADC.

The company is actively pursuing an expedited approval pathway for PDS0101 in HPV16-positive Head and Neck Cancer following positive data from the VERSATILE-002 trial. Hitting those future regulatory and commercial milestones is what converts the current financing into product revenue. The warrants issued in the November 2025 offering also carry an exercise price of $1.00 per share, representing another potential, though non-operating, cash source if exercised.

The current revenue structure is essentially a bridge funded by equity, which is standard for a late-stage biotech advancing pivotal trials. Finance: draft 13-week cash view by Friday.